Citadel Advisors
XGN icon

Citadel Advisors’s Exagen XGN Stock Holding History

Citadel Advisors’s Portfolio XGN Stock Details XGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$693K Buy
231,115
+42,657
+23% +$165K ﹤0.01% 8512
2025
Q4 		$1.15M Buy
188,458
+72,228
+62% +$657K ﹤0.01% 7086
2025
Q3 		$1.28M Buy
+116,230
New +$1.03M ﹤0.01% 7013
2025
Q2 		– Sell
-4,284
Closed -$15.4K – 15396
2025
Q1 		$15.4K Sell
4,284
-18,065
-81% -$68.2K ﹤0.01% 13322
2024
Q4 		$91.6K Sell
22,349
-660
-3% -$2.38K ﹤0.01% 11609
2024
Q3 		$71.1K Sell
23,009
-2,370
-9% -$6.14K ﹤0.01% 11537
2024
Q2 		$46.2K Buy
25,379
+18,139
+251% +$30.7K ﹤0.01% 11852
2024
Q1 		$11.5K Sell
7,240
-13,495
-65% -$26.2K ﹤0.01% 13406
2023
Q4 		$41.3K Buy
+20,735
New +$35.9K ﹤0.01% 11985
2022
Q3 		– Sell
-27,996
Closed -$156K – 13739
2022
Q2 		$160K Buy
+27,996
New +$163K ﹤0.01% 10922

Other funds holding XGN

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $107M AUM
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
FCM
FourWorld Capital Management New York $196M AUM 42.39% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $179M AUM 37.68% 1-Year Est. Return

Citadel Advisors's XGN Position: Q1 2026 in Review

Citadel Advisors increased its Exagen (XGN) stake by 23% in Q1 2026, buying an estimated $165K and bringing the position to 231,115 shares worth $693K. The position accounts for ﹤0.01% of the portfolio, ranked #8512.

Citadel Advisors first reported a position in XGN in Q2 2022 and has held it in 10 quarters since. The position peaked at $1.28M in Q3 2025. 61 funds tracked by Wall St. Rank hold XGN as of Q1 2026.

  • Citadel Advisors held 231,115 shares of Exagen worth $693K as of Q1 2026.
  • Citadel Advisors bought 42,657 Exagen shares in Q1 2026, an estimated $165K.
  • Exagen made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #8512 holding.
  • Citadel Advisors first reported a position in Exagen in Q2 2022 and has held it in 10 quarters since.
  • Citadel Advisors's Exagen position peaked at $1.28M in Q3 2025.
  • 61 funds tracked by Wall St. Rank held Exagen as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.